TUTakeshi Uchikura

Takeshi Uchikura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takeshi Uchikura has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Kenji Momo

    Affiliation Department of Hospital Pharmaceutics, School of Pharmacy, Showa Medical University, Tokyo, Japan

    2 shared publications
  • Tadanori Sasaki

    Department of Appropriate Medication Therapy Management (MTM), School of Pharmacy, Showa University, Tokyo, Japan

    2 shared publications
  • Akitoshi Takuma

    Division of Hospital Pharmaceutics, Department of Hospital Pharmaceutics, School of Pharmacy, Showa Medical University, Shinagawa-ku, Tokyo, Japan

    1 shared publication
  • Daiki Tsuji

    Department of Clinical Pharmaceutics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan

    1 shared publication
  • Daisuke Kikuchi

    First Subcommittee, Committee on Academic, The Japanese Society of Hospital Pharmacists, Tokyo, Japan

    1 shared publication
  • Daisuke Kikuchi

    Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, 1-12-1 Fukumuro, Miyagino-ku, Sendai 983-8512, Miyagi, Japan

    1 shared publication

Latest Publications

  • Open Access

    An exploratory study of patient hospitalization patterns and behavioral risk factors using mobile phone location data

    by Takeshi Uchikura, Kosuke Takata, Masayuki Yoshikawa, Hokuto Morohoshi, Shunichi Ishii, Tomiko Sunaga, Kenji Momo

    This exploratory observational study examined associations between behavioral patterns and hospitalization using geographic analysis of human mobility data. Anonymized GPS-based location data were obtained from users of a mobile location data platform in the Tokyo South Medical Region (Shinagawa and Ota wards) between April 1, 2022, and February 28, 2023. Behavioral patterns, including eating-out frequency and healthcare facility visits, were inferred from movement data. Hospitalization was defined as a hospital stay of at least two consecutive days, identified based on location trajectories. The primary endpoint was the association between eating-out behavior and hospitalization during the observation period. Logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). Venn diagrams were used to illustrate overlapping behavioral characteristics between groups, complementing regression-based analyses by visualizing behaviors that are difficult to capture through average regression effects and by supporting hypothesis generation. In total, 647 participants were included, of whom 580 were classified as outpatients, whereas 67 experienced hospitalization during the study period. Higher odds of hospitalization were observed only among participants who ate out more than eight times per month, compared with those who ate out less frequently (OR = 1.89, 95% CI: 1.05–3.43). No clear association was observed for the other eating-out frequency categories, with confidence intervals that included the null value. Venn diagram analyses suggested that individuals with both frequent outpatient visits and frequent eating-out behavior were more prevalent in the hospitalized group. These findings demonstrate the potential utility of mobile phone-derived mobility data for identifying behavioral patterns associated with hospitalization. However, given the observational design, reliance on indirect behavioral proxies, and missing demographic information (including age and sex), the results should be interpreted with caution. Further studies integrating detailed clinical and demographic data are needed to clarify causal relationships and evaluate the applicability of mobility-based behavioral indicators in healthcare settings.

  • Open Access

    Evaluation of hospital pharmacists’ activities using additional reimbursement for infection prevention as an indicator in small and medium-sized hospitals

    by Yuichi Tasaka, Takeshi Uchikura, Shiro Hatakeyama, Daisuke Kikuchi, Masami Tsuchiya, Ryohkan Funakoshi, Taku Obara

    Background: Hospitals in Japan established the healthcare delivery system from FY 2018 to 2021 by acquiring an additional reimbursement for infection prevention (ARIP) of category 1 or 2. However, research on outcomes of ARIP applications related to the practice of hospital pharmacists is scarce. Methods: This study assessed the activities performed by hospital pharmacists in hospitals with 100 to 299 beds, using ARIP acquirement as an indicator, using data from an annual questionnaire survey conducted in 2020 by the Japanese Society of Hospital Pharmacists on the status of hospital pharmacy departments. Out of the survey items, this study used those related to hospital functions, number of beds, number of pharmacists, whether the hospital is included in the diagnosis procedure combination (DPC) system, average length of stay, and nature of work being performed in the analysis. The relationship between the number of beds per pharmacist and state of implementation of pharmacist services or the average length of hospital stay was considered uncorrelated when the absolute value of the correlation coefficient was within 0–0.2, whereas the relationship was considered to have a weak, moderate, or strong correlation when the absolute value ranged at 0.2–0.4, 0.4–0.7, or 0.7–1, respectively. Results: Responses were received from 3612 (recovery rate: 43.6%) hospitals. Of these, 210 hospitals meeting the criteria for ARIP 1 with 100–299 beds, and 245 hospitals meeting the criteria for ARIP 2 with 100–299 beds, were included in our analysis. There was a significant difference in the number of pharmacists, with a larger number in ARIP 1 hospitals. For the pharmacist services, significant differences were observed, with a more frequency in ARIP 1 hospitals in pharmaceutical management and guidance to pre-hospitalization patients, sterile drug processing of injection drugs and therapeutic drug monitoring. In DPC hospitals with ARIP 1 (173 hospitals) and 2 (105 hospitals), the average number of beds per pharmacist was 21.7 and 24.7, respectively, while the average length of stay was 14.3 and 15.4 d, respectively. Additionally, a weak negative correlation was observed between the number of pharmacist services with “Fairly well” or “Often” and the number of beds per pharmacist for both ARIP 1 (R = -0.207) and ARIP 2 (R = -0.279) DPC hospitals. Furthermore, a weak correlation (R = 0.322) between the average number of beds per pharmacist and the average length of hospital stay was observed for ARIP 2 hospitals. Conclusions: Our results suggest that lower beds per pharmacist might lead to improved pharmacist services in 100–299 beds DPC hospitals with ARIP 1 or 2. The promotion of proactive efforts in hospital pharmacist services and fewer beds per pharmacist may relate to shorter hospital stays especially in small and medium-sized hospitals with ARIP 2 when ARIP acquisition was used as an indicator. These findings may help to accelerate the involvement of hospital pharmacists in infection control in the future.


  • Failure of liposomal amphotericin B therapy in patients with severe pancreatitis complicated by Candida lusitaniae infection

    by Akitoshi Takuma, Erika Inoue, Kenji Momo, Takanori Kuroki, Takeshi Uchikura, Toru Watanabe, Tadanori Sasaki


  • Characteristics of hospitals that report adverse drug reactions: Results of a nationwide survey in Japan

    by Masami Tsuchiya, Daisuke Kikuchi, Shiro Hatakeyama, Yuichi Tasaka, Takeshi Uchikura, Ryohkan Funakoshi, Taku Obara

    What is known and Objective Adverse drug reactions (ADRs) are one of the primary reasons for hospitalization. The spontaneous reporting of ADRs by healthcare professionals is important for issuing post-marketing drug safety measures. The Japanese Society of Hospital Pharmacists (JSHP) conducts a nationwide survey annually. Using data from this large-scale survey, we identified the characteristics of hospitals that reported ADRs to regulatory authorities and pharmaceutical companies. Methods Data were obtained from annual surveys conducted by JSHP from 2015 to 2020. All variables were expressed as categorical variables and tabulated. The Chi-square test was used to compare the categorical variables. The Cochran-Armitage trend test was used to identify significant trends in the proportion of hospitals reporting ADRs. Results and Discussion From 2015 to 2020, 22,362 responses were recorded. There was a significant increase in the proportion of hospitals that reported ADRs with an increase in number of beds and pharmacists (p < 0.0001). The proportion of hospitals reporting ADRs to regulatory authorities was also significantly higher in those charging an additional fee for pharmacist-performed ward operations and in those with an ADR data management section than in hospitals without these attributes (p < 0.0001). What is new and Conclusion Hospitals that submitted ADR reports to the regulatory authorities and pharmaceutical companies charged an additional fee for pharmacist-performed ward operations, had a central ADR data management section, and had fewer beds per pharmacist. This trend was similar, regardless of the size of the hospital.


  • Current Status and the Future of Protection and Utilization of Personal Information at Medical Facilities Based on the Understanding of Related Regulations

    by Takeshi Uchikura, Kenji Momo, Tadanori Sasaki

    In September 2015, “the Act on the Protection of Personal Information” was amended. Accordingly, “the Ethical Guidelines for Medical Research Involving Human Subjects” were also amended. “The Act on Anonymized Medical Data That Are Meant to Contribute to Research and Development in the Medical Field,” which came into effect in May 2018, aims to collect and utilize medical information of each patient from medical institutions for the purpose of research and development in the medical field. Thus, the rules of personal information that need to be followed are changing considerably in the balance between importance of protection and utilization for medical development. Therefore, health care professionals and researchers are required to fully understand the current situation and the future.


  • Open Access

    Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial)

    by Hisanori Shimizu, Kenichi Suzuki, Takeshi Uchikura, Daiki Tsuji, Takeharu Yamanaka, Hironobu Hashimoto, Koichi Goto, Reiko Matsui, Nobuhiko Seki, Toshikazu Shimada, et al.

    We conducted an economic assessment using test data from the phase III TRIPLE study, which examined the efficacy of a 5-hydroxytryptamine 3 receptor antagonist as part of a standard triplet antiemetic regimen including aprepitant and dexamethasone in preventing chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy (HEC). We retrospectively investigated all medicines prescribed for antiemetic purposes within 120 h after the initiation of cisplatin administration during hospitalization. In the TRIPLE study, patients were assigned to treatment with granisetron (GRA) 1 mg (n = 413) or palonosetron (PALO) 0.75 mg (n = 414). The evaluation measure was the cost-effectiveness ratio (CER) assessed as the cost per complete response (CR; no vomiting/retching and no rescue medication). The analysis was conducted from the public healthcare payer’s perspective. The CR rates were 59.1% in the GRA group and 65.7% in the PALO group (P = 0.0539), and the total frequencies of rescue medication use for these groups were 717 (153/413 patients) and 573 (123/414 patients), respectively. In both groups, drugs with antidopaminergic effects were chosen as rescue medication in 86% of patients. The costs of including GRA and PALO in the standard triplet antiemetic regimen were 15,342.8 and 27,863.8 Japanese yen (JPY), respectively. In addition, the total costs of rescue medication use were 73,883.8 (range, 71,106.4–79,017.1) JPY for the GRA group and 59,292.7 (range, 57,707.5–60,972.8) JPY for the PALO group. The CERs (JPY/CR) were 26,263.4 and 42,628.6 for the GRA and PALO groups, respectively, and the incremental cost-effectiveness ratio (ICER) between the groups was 189,171.6 (189,044.8–189,215.5) JPY/CR. We found that PALO was more expensive than GRA in patients who received a cisplatin-based HEC regimen.